Xing D - Search Results

1

A role for BRCA1 in uterine leiomyosarcoma.

Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S. Xing D, et al. Cancer Res. 2009 Nov 1;69(21):8231-5. doi: 10.1158/0008-5472.CAN-09-2543. Epub 2009 Oct 20. Cancer Res. 2009. PMID: 19843854 Free PMC article.

2

A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.

Xing D, Orsulic S. Xing D, et al. Cancer Res. 2006 Sep 15;66(18):8949-53. doi: 10.1158/0008-5472.CAN-06-1495. Cancer Res. 2006. PMID: 16982732 Free PMC article.

3

BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.

Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW. Ibrahim N, et al. Among authors: xing d. Cancer Res. 2010 Sep 15;70(18):7155-65. doi: 10.1158/0008-5472.CAN-10-0668. Epub 2010 Aug 31. Cancer Res. 2010. PMID: 20807817 Free PMC article.

4

A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance.

Xing D, Orsulic S. Xing D, et al. Proc Natl Acad Sci U S A. 2005 May 10;102(19):6936-41. doi: 10.1073/pnas.0502256102. Epub 2005 Apr 28. Proc Natl Acad Sci U S A. 2005. PMID: 15860581 Free PMC article.

5

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.

Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, Goldberg MS. Wang L, et al. Among authors: xing d. Cancer Immunol Res. 2015 Sep;3(9):1030-41. doi: 10.1158/2326-6066.CIR-15-0073. Epub 2015 Jun 8. Cancer Immunol Res. 2015. PMID: 26056145

6

Modeling resistance to pathway-targeted therapy in ovarian cancer.

Xing D, Orsulic S. Xing D, et al. Cell Cycle. 2005 Aug;4(8):1004-6. doi: 10.4161/cc.4.8.1869. Epub 2005 Aug 25. Cell Cycle. 2005. PMID: 15970711 Free PMC article. Review.

7

CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, Poznansky MC. Righi E, et al. Among authors: xing d. Cancer Res. 2011 Aug 15;71(16):5522-5534. doi: 10.1158/0008-5472.CAN-10-3143. Epub 2011 Jul 8. Cancer Res. 2011. PMID: 21742774 Free PMC article.

8

Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.

Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Goldberg MS, et al. Among authors: xing d. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50. doi: 10.1073/pnas.1016538108. Epub 2010 Dec 27. Proc Natl Acad Sci U S A. 2011. PMID: 21187397 Free PMC article.

9

The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.

Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS. Huang J, et al. Among authors: xing d. Biochem Biophys Res Commun. 2015 Aug 7;463(4):551-6. doi: 10.1016/j.bbrc.2015.05.083. Epub 2015 Jun 3. Biochem Biophys Res Commun. 2015. PMID: 26047697

10

MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.

Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr, Behringer RR. Wang Y, et al. Among authors: xing d. Differentiation. 2008 Dec;76(10):1081-92. doi: 10.1111/j.1432-0436.2008.00295.x. Epub 2008 Jul 2. Differentiation. 2008. PMID: 18637025 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,153 results

Search Page

Filters